Cargando…

A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation

Although human antibodies elicited by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein are profoundly boosted upon infection, little is known about the function of N-reactive antibodies. Herein, we isolate and profile a panel of 32 N protein-specific monoclon...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Sisi, Yang, Mei, He, Suhua, Wang, Yueming, Chen, Xiaoxue, Chen, Yao-Qing, Hong, Zhongsi, Liu, Jing, Jiang, Guanmin, Chen, Qiuyue, Zhou, Ziliang, Zhou, Zhechong, Huang, Zhaoxia, Huang, Xi, He, Huanhuan, Zheng, Weihong, Liao, Hua-Xin, Xiao, Fei, Shan, Hong, Chen, Shoudeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113585/
https://www.ncbi.nlm.nih.gov/pubmed/33976229
http://dx.doi.org/10.1038/s41467-021-23036-9
_version_ 1783690894079164416
author Kang, Sisi
Yang, Mei
He, Suhua
Wang, Yueming
Chen, Xiaoxue
Chen, Yao-Qing
Hong, Zhongsi
Liu, Jing
Jiang, Guanmin
Chen, Qiuyue
Zhou, Ziliang
Zhou, Zhechong
Huang, Zhaoxia
Huang, Xi
He, Huanhuan
Zheng, Weihong
Liao, Hua-Xin
Xiao, Fei
Shan, Hong
Chen, Shoudeng
author_facet Kang, Sisi
Yang, Mei
He, Suhua
Wang, Yueming
Chen, Xiaoxue
Chen, Yao-Qing
Hong, Zhongsi
Liu, Jing
Jiang, Guanmin
Chen, Qiuyue
Zhou, Ziliang
Zhou, Zhechong
Huang, Zhaoxia
Huang, Xi
He, Huanhuan
Zheng, Weihong
Liao, Hua-Xin
Xiao, Fei
Shan, Hong
Chen, Shoudeng
author_sort Kang, Sisi
collection PubMed
description Although human antibodies elicited by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein are profoundly boosted upon infection, little is known about the function of N-reactive antibodies. Herein, we isolate and profile a panel of 32 N protein-specific monoclonal antibodies (mAbs) from a quick recovery coronavirus disease-19 (COVID-19) convalescent patient who has dominant antibody responses to the SARS-CoV-2 N protein rather than to the SARS-CoV-2 spike (S) protein. The complex structure of the N protein RNA binding domain with the highest binding affinity mAb (nCoV396) reveals changes in the epitopes and antigen’s allosteric regulation. Functionally, a virus-free complement hyperactivation analysis demonstrates that nCoV396 specifically compromises the N protein-induced complement hyperactivation, which is a risk factor for the morbidity and mortality of COVID-19 patients, thus laying the foundation for the identification of functional anti-N protein mAbs.
format Online
Article
Text
id pubmed-8113585
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-81135852021-05-14 A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation Kang, Sisi Yang, Mei He, Suhua Wang, Yueming Chen, Xiaoxue Chen, Yao-Qing Hong, Zhongsi Liu, Jing Jiang, Guanmin Chen, Qiuyue Zhou, Ziliang Zhou, Zhechong Huang, Zhaoxia Huang, Xi He, Huanhuan Zheng, Weihong Liao, Hua-Xin Xiao, Fei Shan, Hong Chen, Shoudeng Nat Commun Article Although human antibodies elicited by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein are profoundly boosted upon infection, little is known about the function of N-reactive antibodies. Herein, we isolate and profile a panel of 32 N protein-specific monoclonal antibodies (mAbs) from a quick recovery coronavirus disease-19 (COVID-19) convalescent patient who has dominant antibody responses to the SARS-CoV-2 N protein rather than to the SARS-CoV-2 spike (S) protein. The complex structure of the N protein RNA binding domain with the highest binding affinity mAb (nCoV396) reveals changes in the epitopes and antigen’s allosteric regulation. Functionally, a virus-free complement hyperactivation analysis demonstrates that nCoV396 specifically compromises the N protein-induced complement hyperactivation, which is a risk factor for the morbidity and mortality of COVID-19 patients, thus laying the foundation for the identification of functional anti-N protein mAbs. Nature Publishing Group UK 2021-05-11 /pmc/articles/PMC8113585/ /pubmed/33976229 http://dx.doi.org/10.1038/s41467-021-23036-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Kang, Sisi
Yang, Mei
He, Suhua
Wang, Yueming
Chen, Xiaoxue
Chen, Yao-Qing
Hong, Zhongsi
Liu, Jing
Jiang, Guanmin
Chen, Qiuyue
Zhou, Ziliang
Zhou, Zhechong
Huang, Zhaoxia
Huang, Xi
He, Huanhuan
Zheng, Weihong
Liao, Hua-Xin
Xiao, Fei
Shan, Hong
Chen, Shoudeng
A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation
title A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation
title_full A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation
title_fullStr A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation
title_full_unstemmed A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation
title_short A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation
title_sort sars-cov-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113585/
https://www.ncbi.nlm.nih.gov/pubmed/33976229
http://dx.doi.org/10.1038/s41467-021-23036-9
work_keys_str_mv AT kangsisi asarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT yangmei asarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT hesuhua asarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT wangyueming asarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT chenxiaoxue asarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT chenyaoqing asarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT hongzhongsi asarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT liujing asarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT jiangguanmin asarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT chenqiuyue asarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT zhouziliang asarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT zhouzhechong asarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT huangzhaoxia asarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT huangxi asarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT hehuanhuan asarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT zhengweihong asarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT liaohuaxin asarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT xiaofei asarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT shanhong asarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT chenshoudeng asarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT kangsisi sarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT yangmei sarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT hesuhua sarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT wangyueming sarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT chenxiaoxue sarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT chenyaoqing sarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT hongzhongsi sarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT liujing sarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT jiangguanmin sarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT chenqiuyue sarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT zhouziliang sarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT zhouzhechong sarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT huangzhaoxia sarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT huangxi sarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT hehuanhuan sarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT zhengweihong sarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT liaohuaxin sarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT xiaofei sarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT shanhong sarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation
AT chenshoudeng sarscov2antibodycurbsviralnucleocapsidproteininducedcomplementhyperactivation